AI-driven assay development
From precedent to pilot to scale.
Eureka turns published assay literature into a working, scalable protocol for your program. Find precedent, compare strategies, synthesize a pilot, and iterate to scale — without months of trial and error.
Request early access“I drafted a new bench-ready protocol in minutes — for what would have taken me hours across days.”
From precedent to scale
01·Goals & constraints
Define your goals and constraints
Capture the parameters that shape every downstream choice — goal, indication, platform, timeline, throughput, donor pool — so Eureka knows what “fit” means for your program.
Program brief
02·Off-the-shelf options
Discover off-the-shelf alternatives
Surface the off-the-shelf paths forward — commercial kits, CRO partners, and your team’s existing protocols — ranked against your constraints before you build anything new.
Sourcing options
Commercial kit
Promega XYZ
CRO partner
Eurofins · existing MSA
Internal protocol
Team SOP · 2023
Published method
Nat Methods 2024
03·De novo protocol
Construct your de novo protocol
When off-the-shelf doesn’t fit, Eureka drafts a bench-ready de novo protocol shaped to your platform, timeline, donor pool, and team capacity — grounded in precedent.
Pilot assay protocol
Reagents & cell prep
Co-incubation steps
Readout protocol
Controls (isotype, FcR-null)
QC criteria
04·Improve with data
Improve with experimental data to get a scalable assay
Bring in your experimental readouts each round. Eureka recommends parameter changes — controls, donor stratification, FcR variants — until the assay is ready to scale.
Iterate to scale
Our Mission
Stop reinventing the assay wheel.
Eureka is built by Frontier Instruments, a Seattle-based applied-AI lab building the AI infrastructure for physical R&D, starting with life sciences.
Most assay programs spend their first months not running experiments — but reading. Methods papers from adjacent fields. Protocols buried in supplements. Patents that hint at the right control. Conference abstracts that flag a problem nobody’s published. The team that wins the assay race usually isn’t the team with the most reagents. It’s the team that found the right precedent first.
Eureka makes that work tractable. Surface the precedents that actually apply, lay out strategy tradeoffs side by side, draft a pilot protocol shaped to your platform and timeline, then iterate as your data lands. The compounding benefit: your program’s evidence and decisions stick around, so the next assay starts where the last one left off.
We come to this as practitioners. Across orbital rocket manufacturing, de novo antibody models, and global operations infrastructure, the bottleneck was always the same: the gap between what a team can know and the calls it must make. Eureka is the system that closes that gap — so expert judgment goes farther.